Massive registry study aims to unlock secrets of rare thyroid cancer
NCT ID NCT04216732
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses a large registry of 2030 people with medullary thyroid cancer to track how the disease develops and spreads. Researchers will collect medical records, genetic data, and patient surveys to better understand the cancer's natural history. The goal is to improve how advanced medullary thyroid cancer is managed, but no new treatments are being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors better understand how medullary thyroid cancer progresses, potentially leading to improved treatment strategies and patient care.
What could go wrong
This is an observational study, not a treatment trial. It collects data only and does not test any new drug or therapy, so it cannot directly improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV THYROID GLAND MEDULLARY CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-••••
Contact